Key Takeaways
- • ZAP Surgical Systems, Inc., described as a global leader in non-invasive robotic brain surgery, secured $36 million in financing, according to a company announcement dated October 26, 2026.
- • The round was led by Catalio Capital Management, a healthcare and AI-focused investment firm.
- • Baheal, ZAP's strategic partner in China, continued its support in the financing.
- • The company framed the raise as reflecting investor confidence in its technology, commercial momentum, and growth potential in non-invasive robotic therapeutics for neuroscience.
Summary
San Carlos, California-based ZAP Surgical Systems, Inc. announced that it has secured $36 million in financing, led by Catalio Capital Management. The company, which describes itself as a global leader in non-invasive robotic brain surgery, characterized Catalio as a leading innovative healthcare and AI investment firm.
The round also included continued support from Baheal, identified as ZAP's strategic partner in China. The announcement did not disclose valuation, the share of the round contributed by each investor, or the intended use of proceeds beyond the company's general framing of growth.
According to the company, the financing reflects strong investor confidence in ZAP's technology and commercial momentum. Management pointed to growth potential for non-invasive robotic therapeutics across neuroscience as the strategic context for the raise. The source material is a company announcement reproduced by Massinvestor, so the characterizations of the company's position and prospects are the company's own.
The round also included continued support from Baheal, identified as ZAP's strategic partner in China. The announcement did not disclose valuation, the share of the round contributed by each investor, or the intended use of proceeds beyond the company's general framing of growth.
According to the company, the financing reflects strong investor confidence in ZAP's technology and commercial momentum. Management pointed to growth potential for non-invasive robotic therapeutics across neuroscience as the strategic context for the raise. The source material is a company announcement reproduced by Massinvestor, so the characterizations of the company's position and prospects are the company's own.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.